MCID: ANP006
MIFTS: 48

Anaplastic Ependymoma

Categories: Rare diseases, Neuronal diseases

Aliases & Classifications for Anaplastic Ependymoma

MalaCards integrated aliases for Anaplastic Ependymoma:

Name: Anaplastic Ependymoma 49 55 51 69
High-Grade Ependymoma 55

Characteristics:

Orphanet epidemiological data:

55
anaplastic ependymoma
Inheritance: Not applicable; Age of onset: Adolescent,Adult,Childhood;

Classifications:

Orphanet: 55  
Rare neurological diseases


External Ids:

Orphanet 55 ORPHA251646
UMLS via Orphanet 70 C0280788
UMLS 69 C0280788

Summaries for Anaplastic Ependymoma

NIH Rare Diseases : 49 An ependymoma is a tumor that forms when cells in the central nervous system (including the brain and spinal cord) begin to multiple rapidly.  An anaplastic ependymoma is one in which the cells are significantly unusual and grow very quickly.  Ependymomas can occur at any age; when they occur in children, they are more frequently located in the brain, whereas they are more often found in the spinal cord of affected adults.  Symptoms of an ependymoma depend on the age of the patient and the size and location of the tumor.  Though the exact cause of ependymoma is not yet known, it is thought that changes (mutations) in certain genes allow the cells to begin growing quickly.  Treatment for ependymoma begins with surgery to remove as much of the tumor as possible, and may include other therapies as well.  Of all individuals diagnosed with an ependymoma, approximately half are alive five years after their initial diagnosis. Last updated: 3/27/2012

MalaCards based summary : Anaplastic Ependymoma, also known as high-grade ependymoma, is related to subependymoma and malignant ependymoma, and has symptoms including vomiting, seizures and nausea. An important gene associated with Anaplastic Ependymoma is MUC1 (Mucin 1, Cell Surface Associated), and among its related pathways/superpathways are Development EGFR signaling pathway and Development IGF-1 receptor signaling. The drugs Donepezil and Fentanyl have been mentioned in the context of this disorder. Affiliated tissues include brain, spinal cord and bone, and related phenotypes are behavior/neurological and muscle

Related Diseases for Anaplastic Ependymoma

Diseases related to Anaplastic Ependymoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 213)
# Related Disease Score Top Affiliating Genes
1 subependymoma 32.0 GFAP SYP
2 malignant ependymoma 31.4 GFAP NF2 RELA
3 ependymoma 30.5 GFAP MUC1 NF2 RELA S100B SYP
4 ependymoblastoma 30.1 GFAP VIM
5 ganglioglioma 29.7 GFAP S100B SYP
6 myxopapillary ependymoma 29.5 GFAP MUC1 S100B VIM
7 angiocentric glioma 29.3 GFAP S100B SYP VIM
8 hydrocephalus 29.1 GFAP PTEN SYP
9 gliosarcoma 28.9 GFAP PTEN S100B VIM
10 meningioma, familial 27.6 GFAP MUC1 NF2 PTEN S100B SYP
11 malignant adult ependymoma 11.1
12 localized hypertrophic neuropathy 10.5 MUC1 S100B
13 sclerosing perineurioma 10.5 MUC1 S100B
14 reticular perineurioma 10.5 MUC1 S100B
15 non-functioning pituitary adenoma 10.5 MUC1 S100B
16 epithelioid malignant peripheral nerve sheath tumor 10.5 MUC1 S100B
17 myxofibrosarcoma 10.5 MUC1 S100B
18 aggressive digital papillary adenocarcinoma 10.5 MUC1 S100B
19 biphasic synovial sarcoma 10.4 MUC1 VIM
20 malignant mixed mullerian tumor 10.4 MUC1 VIM
21 bednar tumor 10.4 S100B VIM
22 nodular hidradenoma 10.4 MUC1 VIM
23 endometrial mucinous adenocarcinoma 10.4 MUC1 VIM
24 adenofibroma 10.4 MUC1 VIM
25 sarcomatoid mesothelioma 10.4 MUC1 VIM
26 hidradenoma 10.4 MUC1 VIM
27 myopericytoma 10.4 RELA S100B
28 reticulum cell sarcoma 10.4 MUC1 VIM
29 functioning pituitary adenoma 10.4 MUC1 S100B
30 sinonasal undifferentiated carcinoma 10.4 MUC1 SYP
31 mucinous cystadenocarcinoma 10.4 MUC1 VIM
32 chondroid chordoma 10.4 MUC1 VIM
33 mesenchymal chondrosarcoma 10.4 MUC1 VIM
34 juvenile xanthogranuloma 10.4 S100B VIM
35 meningeal melanocytoma 10.4 MUC1 S100B
36 middle ear adenoma 10.4 MUC1 SYP
37 cutaneous fibrous histiocytoma 10.4 S100B VIM
38 dermoid cyst 10.4 MUC1 VIM
39 ovarian small cell carcinoma 10.4 MUC1 SYP
40 hypoganglionosis 10.4 S100B SYP
41 odontogenic myxoma 10.4 S100B VIM
42 mucinous ovarian cystadenoma 10.4 MUC1 SYP
43 supratentorial primitive neuroectodermal tumor 10.3 S100B SYP
44 spindle cell rhabdomyosarcoma 10.3 GFAP MUC1
45 large cell medulloblastoma 10.3 SYP VIM
46 sclerosing hemangioma 10.3 MUC1 SYP
47 intraneural perineurioma 10.3 MUC1 S100B
48 primitive neuroectodermal tumor of the cervix uteri 10.3 GFAP VIM
49 cutaneous leiomyosarcoma 10.3 GFAP VIM
50 retroperitoneal fibrosis 10.3 MDM2 VIM

Graphical network of the top 20 diseases related to Anaplastic Ependymoma:



Diseases related to Anaplastic Ependymoma

Symptoms & Phenotypes for Anaplastic Ependymoma

UMLS symptoms related to Anaplastic Ependymoma:


vomiting, seizures, nausea, headache

MGI Mouse Phenotypes related to Anaplastic Ependymoma:

43
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 9.8 GFAP MDM2 NF2 PTEN S100B SYP
2 muscle MP:0005369 9.55 GFAP MDM2 PTEN RELA VIM
3 nervous system MP:0003631 9.5 GFAP MDM2 NF2 PTEN RELA SYP
4 normal MP:0002873 9.1 GFAP MDM2 PTEN RELA S100B SYP

Drugs & Therapeutics for Anaplastic Ependymoma

Drugs for Anaplastic Ependymoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 200)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Donepezil Approved Phase 3,Phase 2 120014-06-4 3152
2
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
3
Dopamine Approved Phase 3 51-61-6, 62-31-7 681
4
Methylphenidate Approved, Investigational Phase 3 20748-11-2, 113-45-1 4158
5 Pancreatic Polypeptide Investigational Phase 3,Phase 1 59763-91-6
6 Central Nervous System Depressants Phase 3,Phase 1,Phase 2
7 Analgesics Phase 3,Phase 2,Phase 1
8 Adjuvants, Anesthesia Phase 3
9 Central Nervous System Stimulants Phase 3,Phase 2
10 Cholinergic Agents Phase 3,Phase 2
11 Narcotics Phase 3
12 Cholinesterase Inhibitors Phase 3,Phase 2
13 Neurotransmitter Agents Phase 3,Phase 2
14 Analgesics, Opioid Phase 3
15 Nootropic Agents Phase 3,Phase 2
16 Anesthetics Phase 3
17 Anesthetics, General Phase 3
18 Anesthetics, Intravenous Phase 3
19 Peripheral Nervous System Agents Phase 3,Phase 2,Phase 1
20 Liver Extracts Phase 3,Phase 2,Phase 1
21 Dopamine Agents Phase 3
22 Neurotransmitter Uptake Inhibitors Phase 3
23 Dexmethylphenidate Hydrochloride Phase 3
24 Dopamine Uptake Inhibitors Phase 3
25 Cola Nutraceutical Phase 3,Phase 1
26
Ethanol Approved Phase 1, Phase 2 64-17-5 702
27
Dacarbazine Approved, Investigational Phase 2,Phase 1 4342-03-4 5351166
28
Temozolomide Approved, Investigational Phase 2,Phase 1 85622-93-1 5394
29
Carmustine Approved, Investigational Phase 1, Phase 2 154-93-8 2578
30
Doxorubicin Approved, Investigational Phase 2 23214-92-8 31703
31
Vincristine Approved, Investigational Phase 2 2068-78-2, 57-22-7 5978
32
Paclitaxel Approved, Vet_approved Phase 2,Phase 1 33069-62-4 36314
33
Etoposide Approved Phase 2 33419-42-0 36462
34
Cisplatin Approved Phase 2,Phase 1 15663-27-1 2767 441203 84093
35
Topotecan Approved, Investigational Phase 2 119413-54-6, 123948-87-8 60700
36
Methotrexate Approved Phase 2 1959-05-2, 59-05-2 126941
37
Irinotecan Approved, Investigational Phase 2 97682-44-5, 100286-90-6 60838
38
Tamoxifen Approved Phase 2 10540-29-1 2733526
39
Carboplatin Approved Phase 2,Phase 1 41575-94-4 10339178 38904 498142
40
Cyclophosphamide Approved, Investigational Phase 2 50-18-0, 6055-19-2 2907
41 Piracetam Approved, Investigational Phase 2 7491-74-9
42
Iodine Approved, Investigational Phase 1, Phase 2 7553-56-2 807
43
Miconazole Approved, Investigational, Vet_approved Phase 2 22916-47-8 4189
44
Everolimus Approved Phase 2 159351-69-6 6442177
45 Thiotepa Approved, Investigational Phase 2,Phase 1 52-24-4 5453
46
Lenograstim Approved, Investigational Phase 2,Phase 1 135968-09-1
47
Modafinil Approved, Investigational Phase 2 68693-11-8 4236
48
Pregabalin Approved, Illicit, Investigational Phase 2 148553-50-8 5486971
49
Aldesleukin Approved Phase 2,Phase 1 110942-02-4, 85898-30-2
50
Bevacizumab Approved, Investigational Phase 2 216974-75-3

Interventional clinical trials:

(show top 50) (show all 86)

# Name Status NCT ID Phase Drugs
1 Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
2 Donepezil in Treating Patients Who Have Undergone Radiation Therapy for Brain Tumors Completed NCT00369785 Phase 3 donepezil hydrochloride;Placebo
3 Methylphenidate to Improve Quality of Life in Patients Undergoing Radiation Therapy for Brain Tumors Terminated NCT00031798 Phase 3 methylphenidate hydrochloride
4 Phase I/II Trial of Safety and Anti-tumor Efficacy of AXL1717(Picropodophyllin) in the Treatment of Recurrent Malignant Astrocytomas Unknown status NCT01721577 Phase 1, Phase 2 AXL1717
5 Dose-Dense Temozolomide + Lapatinib for Recurrent Ependymoma Unknown status NCT00826241 Phase 2 Temozolomide;Lapatinib
6 Carmustine Followed By Surgery in Treating Patients With Recurrent Supratentorial Malignant Glioma or Metastatic Brain Neoplasm Unknown status NCT00009854 Phase 1, Phase 2 carmustine in ethanol
7 Etoposide Plus Cisplatin in Treating Patients With Recurrent Ependymomas Completed NCT00002876 Phase 2 cisplatin;etoposide
8 Combination Chemotherapy Plus Radiation Therapy in Treating Adult Patients With Brain Cancer Completed NCT00003309 Phase 2 cisplatin;cyclophosphamide;etoposide;vincristine sulfate
9 Poly-ICLC in Treating Patients With Recurrent or Progressive Anaplastic Glioma Completed NCT00058123 Phase 2 poly ICLC
10 Imetelstat Sodium in Treating Younger Patients With Recurrent or Refractory Brain Tumors Completed NCT01836549 Phase 2 imetelstat sodium
11 Bevacizumab in Reducing CNS Side Effects in Patients Who Have Undergone Radiation Therapy to the Brain for Primary Brain Tumor, Meningioma, or Head and Neck Cancer Completed NCT00492089 Phase 2 bevacizumab;placebo
12 Veliparib and Temozolomide in Treating Patients With Recurrent Glioblastoma Completed NCT01026493 Phase 1, Phase 2 temozolomide 60 mg x 21 days;temozolomide 75 mg x 21 days;ABT-888 20 mg x 21 days;ABT-888 40 mg x 21 days;Temozolomide 150 mg x 5 days;ABT-888 40 mg x 5 days
13 Armodafinil in Treating Fatigue Caused By Radiation Therapy in Patients With Primary Brain Tumors Completed NCT01032200 Phase 2 Armodafinil
14 Levetiracetam or Pregabalin in Treating Seizures in Patients Undergoing Chemotherapy and/or Radiation Therapy For Primary Brain Tumors Completed NCT00629889 Phase 2 levetiracetam;pregabalin
15 Tamoxifen, Carboplatin, and Topotecan in Treating Patients With CNS Metastases or Recurrent Brain or Spinal Cord Tumors Completed NCT00541138 Phase 2 carboplatin;tamoxifen citrate;topotecan hydrochloride
16 Temozolomide in Treating Patients With Recurrent Glioblastoma Multiforme or Other Malignant Glioma Completed NCT00498927 Phase 2 temozolomide
17 Dynamic Contrast-Enhanced Magnetic Resonance Imaging (DCE-MRI) With Bevacizumab and Irinotecan for Malignant Glioma Completed NCT00352521 Phase 2 bevacizumab;irinotecan
18 Magnetic Resonance Imaging and Magnetic Resonance Spectroscopic Imaging in Evaluating Patients Who Are Undergoing Treatment for Gliomas Completed NCT00274755 Phase 2 chemotherapy
19 Combination Chemotherapy Followed by Radiation Therapy in Treating Patients With Medulloblastoma, Supratentorial Primitive Neuroectodermal Tumor, or Ependymoma Completed NCT00006258 Phase 2 cisplatin;cyclophosphamide;etoposide;methotrexate;vincristine sulfate
20 Chemotherapy and Vaccine Therapy Followed by Bone Marrow or Peripheral Stem Cell Transplantation and Interleukin-2 in Treating Patients With Recurrent or Refractory Brain Cancer Completed NCT00014573 Phase 2 carmustine;cisplatin;cyclophosphamide;paclitaxel
21 Radiolabeled Monoclonal Antibody Therapy in Treating Patients With Primary Brain Tumors Completed NCT00003478 Phase 1, Phase 2
22 Phase II Studies Of Donepezil And Ginkgo Biloba In Irradiated Brain Tumor Completed NCT00070161 Phase 2 donepezil hydrochloride
23 Radiolabeled Monoclonal Antibody Therapy in Treating Patients With Primary or Metastatic Brain Cancers Completed NCT00002752 Phase 1, Phase 2
24 Thiotepa Followed by Peripheral Stem Cell or Bone Marrow Transplant in Treating Patients With Malignant Glioma Completed NCT00008008 Phase 2 cyclophosphamide;thiotepa
25 Combination Chemotherapy and Tamoxifen in Treating Patients With Solid Tumors Completed NCT00002608 Phase 2 cisplatin;doxorubicin hydrochloride;tamoxifen citrate
26 Carboplatin and Bevacizumab for Recurrent Ependymoma Recruiting NCT01295944 Phase 2 Carboplatin;Bevacizumab
27 Everolimus for Children With Recurrent or Progressive Ependymoma Recruiting NCT02155920 Phase 2 Everolimus
28 Phase II Pediatric Study With Dabrafenib in Combination With Trametinib in Patients With HGG Recruiting NCT02684058 Phase 2 dabrafenib;trametinib
29 Efficacy of Hypofractionated XRT w/Bev. + Temozolomide for Recurrent Gliomas Active, not recruiting NCT01478321 Phase 2 Temozolomide
30 Observation or Radiation Therapy and/or Chemotherapy and Second Surgery in Treating Children Who Have Undergone Surgery for Ependymoma Active, not recruiting NCT00027846 Phase 2 carboplatin;cyclophosphamide;etoposide;vincristine sulfate;Mesna
31 Iodine I 131 Monoclonal Antibody 3F8 in Treating Patients With Central Nervous System Cancer or Leptomeningeal Cancer Active, not recruiting NCT00445965 Phase 2
32 Antineoplaston Therapy in Treating Patients With Ependymoma Terminated NCT00003479 Phase 2 Antineoplaston therapy (Atengenal + Astugenal)
33 Ritonavir and Lopinavir in Treating Patients With Progressive or Recurrent High-Grade Glioma Terminated NCT01095094 Phase 2 ritonavir;lopinavir
34 Photodynamic Therapy in the Treatment of Malignant Intracranial Tumors Withdrawn NCT00243490 Phase 2
35 Functional Magnetic Resonance Imaging and 1H-Nuclear Magnetic Resonance Spectroscopic Imaging in Treating Patients With Newly Diagnosed Brain Tumors Withdrawn NCT00005083 Phase 2
36 Enzastaurin and Temozolomide in Treating Patients With Primary Gliomas Unknown status NCT00516607 Phase 1 enzastaurin hydrochloride;temozolomide
37 Lonafarnib and Temozolomide in Treating Patients With Recurrent Primary Supratentorial Gliomas Unknown status NCT00083096 Phase 1 lonafarnib;temozolomide
38 Photodynamic Therapy With Porfimer Sodium in Treating Patients With Refractory Brain Tumors Unknown status NCT00002647 Phase 1 verteporfin
39 Phase I Study of Cellular Immunotherapy for Recurrent/Refractory Malignant Glioma Using Intratumoral Infusions of GRm13Z40-2, An Allogeneic CD8+ Cytolitic T-Cell Line Genetically Modified to Express the IL 13-Zetakine and HyTK and to be Resistant to Gluco Completed NCT01082926 Phase 1
40 Gamma-Secretase Inhibitor RO4929097 and Cediranib Maleate in Treating Patients With Advanced Solid Tumors Completed NCT01131234 Phase 1 Gamma-Secretase Inhibitor RO4929097;Cediranib Maleate
41 Erlotinib in Treating Patients With Solid Tumors and Liver or Kidney Dysfunction Completed NCT00030498 Phase 1 erlotinib hydrochloride
42 RO4929097, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Malignant Glioma Completed NCT01119599 Phase 1 Gamma-Secretase Inhibitor RO4929097;Temozolomide
43 Mibefradil Dihydrochloride and Temozolomide in Treating Patients With Recurrent Glioma Completed NCT01480050 Phase 1 temozolomide;Mibefradil
44 Cellular Adoptive Immunotherapy Using Genetically Modified T-Lymphocytes in Treating Patients With Recurrent or Refractory High-Grade Malignant Glioma Completed NCT00730613 Phase 1
45 Carmustine in Treating Patients With Recurrent Malignant Glioma Completed NCT00004028 Phase 1 carmustine
46 Bortezomib and Temozolomide in Treating Patients With Brain Tumors or Other Solid Tumors That Have Not Responded to Treatment Completed NCT00544284 Phase 1 bortezomib;temozolomide
47 Sodium Stibogluconate and IFNa-2b Followed By CDDP, VLB and DTIC Treating Pts.With Advanced Melanoma or Other Cancers Completed NCT00498979 Phase 1 cisplatin;sodium stibogluconate;dacarbazine;vinblastine
48 Imatinib Mesylate, Vatalanib, and Hydroxyurea in Treating Patients With Recurrent or Relapsed Malignant Glioma Completed NCT00387933 Phase 1 hydroxyurea;imatinib mesylate;vatalanib
49 Monoclonal Antibody Therapy in Treating Patients With Recurrent Gliomas Completed NCT00002753 Phase 1
50 Yttrium Y 90 SMT 487 in Treating Patients With Refractory or Recurrent Cancer Completed NCT00006368 Phase 1

Search NIH Clinical Center for Anaplastic Ependymoma

Genetic Tests for Anaplastic Ependymoma

Anatomical Context for Anaplastic Ependymoma

MalaCards organs/tissues related to Anaplastic Ependymoma:

38
Brain, Spinal Cord, Bone, Bone Marrow, Liver, T Cells, Kidney

Publications for Anaplastic Ependymoma

Articles related to Anaplastic Ependymoma:

(show top 50) (show all 93)
# Title Authors Year
1
RELA fusion-positive anaplastic ependymoma: molecular characterization and advanced MR imaging. ( 29063976 )
2018
2
"Drop" Metastases from an Operated Case of Intracranial Anaplastic Ependymoma Identified on Fluoro-2-deoxyglucose Positron Emission Tomography/Computed Tomography. ( 28242994 )
2017
3
Spinal cord anaplastic ependymoma induced by radiation treatment of breast cancer. ( 28555490 )
2017
4
Encouraging option of multi-staged gross total resection for a C11orf-RelA fusion-positive supratentorial anaplastic ependymoma. ( 28831588 )
2017
5
Rapid autopsy of a patient with recurrent anaplastic ependymoma. ( 28942746 )
2017
6
Hormonal based treatment of ovarian anaplastic ependymoma with anastrozole. ( 28393092 )
2017
7
Anaplastic Ependymoma With Ganglionic Differentiation: Report of a Rare Case and Implications in Diagnosis. ( 28554236 )
2017
8
Multifocal intradural extramedullary anaplastic ependymoma of the spine. ( 29354756 )
2017
9
Angiocentric glioma transformed into anaplastic ependymoma: Review of the evidence for malignant potential. ( 27742374 )
2016
10
Magnetic resonance imaging findings of extraventricular anaplastic ependymoma: A report of 11 cases. ( 27602137 )
2016
11
Re-irradiation of recurrent anaplastic ependymoma using radiosurgery or fractionated stereotactic radiotherapy. ( 26682738 )
2016
12
Supratentorial extraventricular WHO grade III (anaplastic) ependymoma 17 years after total removal of WHO grade II ependymoma of the fourth ventricle. ( 27215793 )
2016
13
Pure extra-axial supratentorial anaplastic ependymoma with no cortical attachment: A rare case. ( 26954823 )
2016
14
Brain Tumor in an In Vitro Fertilization-Facilitated Pregnancy: Fourth Ventricle Anaplastic Ependymoma in the Second Trimester. ( 27330925 )
2016
15
Radiation-induced anaplastic ependymoma mimicking a skull base meningioma: A case report. ( 26893630 )
2016
16
Paediatric Intracranial Anaplastic Ependymoma: The Role of Multiple Surgical Resections for Disease Relapse in Maintaining Quality of Life and Prolonged Survival. ( 25871983 )
2015
17
Role of Evaluating MGMT Status and 1p36 Deletion in Radiosurgery-Induced Anaplastic Ependymoma That Rapidly and Completely Resolved by Temozolomide Alone: Case Report and Review of the Literature. ( 26251808 )
2015
18
Anaplastic ependymoma of spinal cord presented with lower back pain. ( 25843250 )
2015
19
Anaplastic Ependymoma in a Child With Sickle Cell Anemia: A Case Report Highlighting Treatment Challenges for Young Children With Central Nervous System Tumors and Underlying Vasculopathy. ( 26488903 )
2015
20
Supratentorial extraventricular anaplastic ependymoma with extracranial metastasis. ( 25455735 )
2015
21
Temozolomide Treatment for Pediatric Refractory Anaplastic Ependymoma With Low MGMT Protein Expression. ( 26305586 )
2015
22
An 11 Year Old Child with a Right Parieto-Occipital Lesion. Anaplastic Ependymoma (WHO Grade III) with Granular Cell Features. ( 26086056 )
2015
23
An extraneural primary anaplastic ependymoma at the subcutaneous inguinal region: Report of a rare case. ( 26549094 )
2015
24
Ectopic cortical anaplastic ependymoma: an unusual case report and literature review. ( 25051164 )
2014
25
Supratentorial extraventricular anaplastic ependymoma in a child. ( 24623545 )
2014
26
Treatment of Ovarian Anaplastic Ependymoma by an Aromatase Inhibitor. ( 24413241 )
2014
27
Anaplastic ependymoma of the third ventricle. ( 24643478 )
2014
28
Supratentorial Extraventricular Anaplastic Ependymoma Presenting with Repeated Intratumoral Hemorrhage. ( 25408930 )
2014
29
Radiation-induced anaplastic ependymoma with a remarkable clinical response to temozolomide: a case report. ( 23163298 )
2013
30
Cortical anaplastic ependymoma with significant desmoplasia: a case report and literature review. ( 24455359 )
2013
31
Supratentorial extraventricular anaplastic ependymoma in an adult with repeated intratumoral hemorrhage. ( 23546851 )
2013
32
Extra and intramedullary anaplastic ependymoma in thoracic spinal cord. ( 24757483 )
2013
33
Anaplastic ependymoma with ependymoblastic multilayered rosettes. ( 23791209 )
2013
34
Supratentorial gross-totally resected non-anaplastic ependymoma: population based patterns of care and outcomes analysis. ( 24085643 )
2013
35
Cisplatin and temozolomide combination in the treatment of supratentorial anaplastic ependymoma. ( 24192541 )
2013
36
Anaplastic ependymoma with holocordal and intracranial meningeal carcinomatosis and holospinal bone metastases. ( 23422903 )
2013
37
A headache presenting in the emergency room, a clinical manifestation of an unfortunate diagnosis (grade III left frontal anaplastic ependymoma with 1p deletion). ( 23912654 )
2013
38
Anaplastic ependymoma simulating glioblastoma in the cerebrum of an adult. ( 21833575 )
2012
39
Supratentorial extra-axial anaplastic ependymoma mimicking a meningioma. ( 22406799 )
2012
40
Purely cortical anaplastic ependymoma. ( 23119204 )
2012
41
An anaplastic ependymoma presenting as an intrinsic brainstem glioma. ( 22406810 )
2012
42
Tandem high-dose chemotherapy and autologous stem cell transplantation for anaplastic ependymoma in children younger than 3 years of age. ( 22081297 )
2012
43
Metronomic cyclophosphamide with cisplatin and bevacizumab: a new chemotherapeutic regimen for refractory anaplastic ependymoma. ( 23155280 )
2012
44
Sacrococcygeal myxopapillary ependymoma with anaplastic ependymoma component in an infant. ( 23560014 )
2012
45
Cystic with mural nodule: Unusual radiological presentation of supratentorial anaplastic ependymoma. ( 23248684 )
2012
46
Spinal intradural, extramedullary anaplastic ependymoma with an extradural component: Case report and review of the literature. ( 21918734 )
2011
47
Metachronous occurrence of a temporal ganglioglioma and a bifrontal anaplastic ependymoma: coincidence or an explainable pathological curiosity? ( 21501061 )
2011
48
Isolated extracranial recurrence of anaplastic ependymoma. ( 20830772 )
2011
49
Extraventricular anaplastic ependymoma with metastasis to scalp and neck. ( 21222217 )
2011
50
Recurrent posterior fossa anaplastic ependymoma with prominent chondroid metaplasia: a case report and review of literature. ( 21045418 )
2010

Variations for Anaplastic Ependymoma

Expression for Anaplastic Ependymoma

Search GEO for disease gene expression data for Anaplastic Ependymoma.

Pathways for Anaplastic Ependymoma

GO Terms for Anaplastic Ependymoma

Cellular components related to Anaplastic Ependymoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 neuron projection GO:0043005 8.92 NF2 PTEN SYP VIM

Biological processes related to Anaplastic Ependymoma according to GeneCards Suite gene sharing:

(show all 13)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of cell proliferation GO:0008284 9.8 MDM2 PTEN RELA S100B
2 cellular response to organic substance GO:0071310 9.52 MDM2 SYP
3 response to morphine GO:0043278 9.51 MDM2 RELA
4 cellular response to hypoxia GO:0071456 9.5 MDM2 PTEN S100B
5 regulation of neuronal synaptic plasticity GO:0048168 9.48 S100B SYP
6 cellular response to peptide hormone stimulus GO:0071375 9.46 MDM2 RELA
7 astrocyte development GO:0014002 9.43 GFAP VIM
8 intermediate filament organization GO:0045109 9.4 GFAP VIM
9 response to inorganic substance GO:0010035 9.37 PTEN RELA
10 negative regulation of neuron projection development GO:0010977 9.33 GFAP MDM2 VIM
11 Bergmann glial cell differentiation GO:0060020 9.26 GFAP VIM
12 intermediate filament-based process GO:0045103 8.96 GFAP VIM
13 long-term synaptic potentiation GO:0060291 8.8 GFAP PTEN S100B

Molecular functions related to Anaplastic Ependymoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 identical protein binding GO:0042802 9.17 GFAP MDM2 PTEN RELA S100B SYP

Sources for Anaplastic Ependymoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
27 GO
28 GTR
29 HGMD
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 MedGen
41 MeSH
42 MESH via Orphanet
43 MGI
45 NCI
46 NCIt
47 NDF-RT
50 NINDS
51 Novoseek
53 OMIM
54 OMIM via Orphanet
58 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....